Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole

Journal of Controlled Release

Volumn 192, Issue , 2014, Pages 95-102

  Kumar, Sumit ^a,b   Shen, Jie ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Amorphous itraconazole; Antisolvent precipitation; DoE; Melt quench; Nano amorphous; Spray drying

Indexed keywords

BIOCHEMISTRY; DISSOLUTION; PARTICLE SIZE; POWDERS;

ANTI-SOLVENT PRECIPITATIONS; BIOAVAILABILITY STUDY; COMBINATION APPROACHES; HIGH MOLECULAR WEIGHT; ITRACONAZOLE; MELT-QUENCH; ORAL BIOAVAILABILITIES; STABILIZER CONCENTRATION;

SPRAY DRYING;

ITRACONAZOLE; LACTOSE; MALTODEXTRIN; STABILIZING AGENT; SUCROSE; TREHALOSE; POWDER; STEROL 14ALPHA DEMETHYLASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BIREFRINGENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; GLASS TRANSITION TEMPERATURE; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; PARTICLE SIZE; POWDER; PRECIPITATION; PRIORITY JOURNAL; SPRAY DRYING; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DESICCATION; DEVICES; EQUIPMENT DESIGN; MALE; ORAL DRUG ADMINISTRATION; SOLUBILITY; SPRAGUE DAWLEY RAT; X RAY DIFFRACTION;

14-ALPHA DEMETHYLASE INHIBITORS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMICAL PRECIPITATION; DESICCATION; DRUG COMPOUNDING; EQUIPMENT DESIGN; ITRACONAZOLE; MALE; PARTICLE SIZE; POWDERS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; X-RAY DIFFRACTION;

EID: 84904890958     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.059     Document Type: Article

References (30)

1. C. Lipinski Poor aqueous solubility - an industry wide problem in drug discovery Am. Pharm. Rev. 5 2002 82 85
2. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 1-3 Mar 1 2001 3 26 (Pubitemid 33653411)
3. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 1 Jul-Aug 2000 235 249
4. P. Gribbon, and A. Sewing High-throughput drug discovery: what can we expect from HTS? Drug Discov. Today 10 1 Jan 1 2005 17 22 (Pubitemid 40164815)
5. M.M. Hann, and T.I. Oprea Pursuing the leadlikeness concept in pharmaceutical research Curr. Opin. Chem. Biol. 8 2004 255 263 (Pubitemid 38759400)
6. S. Yamashita, and T. Fububayashi In vitro-in vivo correlations: Application to water insoluble drugs Bull. Tech. Gattefosse N91 1998 25 31
7. G.W. Caldwell et al. The new pre-preclinical paradigm: Compound optimization in early and late phase drug discovery Curr. Top. Med. Chem. 1 5 2001 353 366
8. T. Hartmann et al. ADME related profiling in 96 and 384 well plate format-a novel and robust HT-assay for the determination of lipophilicity and serum albumin binding Curr. Drug Deliv. 3 2 2006 181 192 (Pubitemid 43725015)
9. R.A. Prentis, Y. Lis, and S.R. Walker Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br. J. Clin. Pharmacol. 25 3 1988 387 396
10. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020966s022lbl. pdf
11. E.M. Merisko-Liversidge, and G.G. Liversidge Drug nanoparticles: Formulating poorly water-soluble compounds Toxicol. Pathol. 36 1 2008 43 48
12. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2 2003 113 120 (Pubitemid 36184748)
13. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanocrystal drug particles: Resolving pharmaceutical formulation issues associated with poorly water-soluble compounds Abstract #PMSE 444 September 7-11, 2003 The 226th National ACS meeting New York, NY
14. S.W. Thomson On the equilibrium of vapour at a curved surface of liquid Philos. Mag. 42 282 1871 448 452 (Series 4)
15. B. Van Eerdenbrugh, J. Vermant, J.A. Martens, L. Froyen, J.V. Humbeeck, and G. Van den Mooter et al. Solubility increases associated with crystalline drug nanoparticles: methodologies and significance Mol. Pharm. 7 5 Oct 4 2010 1858 1870
16. R. Peagram, R. Gibb, and K. Sooben The rational selection of formulations for preclinical studies-an industrial perspective Bull. Tech. Gattefosse 98 2005 53 64
17. W.L. Chiou, and S. Riegelman Oral absorption of griseofulvin in dogs: increased absorption via solid dispersion in polyethylene glycol 6000 J. Pharm. Sci. 59 7 1970 937 942
18. B.C. Hancock, and M. Parks What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17 4 2000 397 404 (Pubitemid 30395293)
19. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 1 2000 47 60 (Pubitemid 30326688)
20. A.T. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 10 1999 1058 1066
21. Ji-Yao Zhang et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants Int. J. Pharm. 323 2006 153 160 (Pubitemid 44397363)
22. Wen-Zhen Zhu et al. Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microschannel reactor Int. J. Pharm. 395 2010 260 265
23. Microfluidics synthesis of amorphous cefuroxime axetil nanoparticles with size-dependent and enhanced dissolution rate Control. Eng. J. 161 2010 844 851
24. L. Lindfors et al. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening Langmuir 22 2006 906 910 (Pubitemid 43282149)
25. X. Chen et al. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution Int. J. Pharm. 242 2002 3 14
26. S. Kumar, and D.J. Burgess Nanosuspension Long acting injections and implants 2012 239 262 (Chapter 13)
27. L.A. Wegiel et al. Mid-infrared spectroscopy as a polymer selection tool for formulating amorphous solid dispersions J. Pharm. Pharmacol. 66 2 2014 244 255
28. D. Mou et al. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility Int. J. Pharm. 413 2011 237 244
29. K. Six, G. Verreck, J. Peeters, P. Augustijns, R. Kinget, and G. Van den Mooter Characterization of glassy itraconazole: a comparative study of its molecular mobility below T(g) with that of structural analogues using MTDSC Int. J. Pharm. 213 1-2 2011 163 173
30. W.S. Cheow et al. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles Mol. Pharm. 11 5 2014 1611 1620